peptide protocols FAQ

GHRP-6 stimulates ghrelin release, the hormone responsible for appetite signaling, which is why some athletes experience pronounced hunger 30–60 minutes post-injection. If this disrupts caloric control or leads to poor food choices during training, switch to Ipamorelin. It provides selective GH release without the ghrelin surge. Alternatively, time GHRP-6 administration immediately before a planned meal so the hunger spike coincides with scheduled nutrition intake. Do not fight the hunger with willpower alone; adjust the protocol instead.

BPC-157 does not produce acute effects. Collagen remodeling and angiogenesis require 10–14 days of consistent administration before measurable tissue changes occur. If you're three weeks into a 16-week marathon build and introduce BPC-157 expecting instant pain relief, you'll be disappointed. Continue daily dosing for a minimum of 21 days while maintaining structured training load. The peptide amplifies repair signaling, but tissue turnover operates on biological timelines that peptides can accelerate, not bypass. Tendon stiffness or inflammation should begin resolving in week three if the compound is working.

Peptides like BPC-157 and TB-500 do not require uninterrupted daily dosing to retain efficacy. Tissue repair pathways remain upregulated for 48–72 hours post-administration. Missing 2–3 doses during travel or taper is not catastrophic. Resume your standard protocol upon return without attempting to 'catch up' by doubling doses. GHRP-6 and Ipamorelin, however, produce acute GH pulses. Missing doses simply means fewer GH release events that week. Adjust expectations accordingly; peptides are tools that enhance outcomes over weeks and months, not sessions.

Rotate injection sites systematically. Abdomen, thighs, deltoids. To prevent localized tissue buildup or irritation. Lipohypertrophy (fatty lumps under the skin) occurs when the same site is used repeatedly, disrupting normal fat cell distribution. If irritation develops, skip that site for 7–10 days and apply a warm compress to promote circulation. Ensure you're using insulin syringes (29–31 gauge) and injecting at the correct subcutaneous depth. Too shallow causes bruising, too deep risks intramuscular injection which is less effective for peptide delivery.

Extend the observation window to week 6–8 before concluding the peptide failed. TB-4's mechanism requires sustained transcription factor activation. Effects plateau around week 5–6 in most models, meaning week 4 data captures the ascending phase, not the peak effect. Verify peptide storage temperature logs: if any vial was stored above 8°C for more than 24 hours, potency loss is the likely explanation. Request third-party functional assay data (not just HPLC purity) from your peptide supplier. Sequence accuracy doesn't confirm bioactivity.

Combination protocols with VEGF, IGF-1, or bFGF can accelerate observable effects by 20–30% because you're activating complementary pathways simultaneously. TB-4 upregulates VEGF transcription; exogenous VEGF provides immediate receptor activation. The combination shortens the lag between TB-4 administration and angiogenesis. The trade-off: isolating which peptide drove which effect becomes impossible, so combination protocols work for applied research but complicate mechanistic studies. Dose each peptide at 50–75% of its solo therapeutic dose to avoid receptor saturation.

Switch to molecular endpoints measurable within 48–72 hours: VEGF mRNA via RT-PCR, HIF-1α protein via Western blot, or endothelial cell migration via scratch assay. These readouts confirm TB-4 is activating its target pathways even if structural tissue changes haven't appeared yet. Daily dosing instead of twice-weekly can compress timelines by 15–20%, but it won't override the biological rate-limiting steps. If your funding or timeline genuinely can't accommodate 6–8 weeks, TB-4 may not be the right peptide for your model. Consider acute-phase modulators like bFGF or PDGF for shorter observation windows.

Verify three variables before concluding the peptide isn't working: (1) administration timing—are you dosing 60–90 minutes before actual sleep onset, not just 'before bed'? (2) Reconstitution accuracy—did you inject bacteriostatic water down the vial wall rather than directly onto the peptide? (3) Baseline sleep quality measurement—DSIP extends slow-wave sleep, but if your baseline deep sleep percentage is already 18–20% of total sleep time, there may be limited room for improvement. Use a sleep tracker that measures sleep stages to confirm whether slow-wave sleep duration is increasing even if subjective 'feeling' hasn't changed.

DSIP administered outside the circadian melatonin rise window shows significantly reduced efficacy for sleep architecture goals. If the protocol mandate is daytime dosing, expect minimal slow-wave sleep extension—DSIP's receptor engagement depends on the hormonal environment present during natural sleep onset. Some stress modulation effects (cortisol suppression) may still occur, but the primary recovery mechanisms tied to deep sleep won't activate.

No. Administer the standard dose (50–100mcg) on your next scheduled night and continue the protocol. DSIP doesn't accumulate in the system—it has a short half-life (approximately 15–20 minutes in circulation) and works acutely on the night it's administered. Doubling the dose won't 'catch up' and may cause unnecessary receptor saturation without added benefit.

Discard it and reconstitute a fresh vial. Temperature excursions above 8°C for more than 2–3 hours begin irreversible peptide bond degradation—there's no way to visually confirm whether the peptide is still active, and using degraded DSIP means dosing with an unknown (likely reduced) potency. The financial loss of one vial is far smaller than the research validity loss of inconsistent dosing.

Discard the vial and reconstitute a fresh dose. Peptide stability isn't salvageable after prolonged room-temperature exposure. A study from Purdue University measured ipamorelin potency after temperature excursions and found that solutions held at 22°C for 12 hours retained only 61% of their original GH-stimulating activity compared to refrigerated controls. The degradation isn't visible. The solution looks identical, but receptor binding affinity drops irreversibly. Attempting to compensate by increasing dose doesn't restore efficacy because the degradation products compete for receptor sites without triggering downstream signaling.

Verify injection timing relative to meals and confirm dosing accuracy. The most common protocol failures stem from dosing in fed states or using diluted solutions. Ipamorelin's mechanism requires fasted-state ghrelin receptor availability; even a small snack within 60 minutes of injection can suppress GH release by 40–60%. If timing and dosing are correct, consider that subjective recovery markers (sleep quality, muscle soreness reduction) typically manifest before measurable tissue changes. Clinical trials show IGF-1 elevation begins around day 10–14, with functional recovery improvements following 3–4 weeks later.

Discard it immediately. Cloudiness or visible particles indicate protein aggregation or bacterial contamination—both render the solution unsafe and ineffective. Properly reconstituted IGF-1 LR3 should be clear and colourless. Aggregation occurs when the peptide is exposed to temperatures above 25°C for extended periods or when reconstituted with non-sterile water. Injecting aggregated protein can trigger immune responses that reduce future receptor sensitivity. Our team recommends reconstituting only the volume you'll use within 2 weeks to minimise degradation risk.

Resume at the next scheduled dose—do not double-dose. Missing a single injection reduces cumulative anabolic signaling but doesn't reset the recovery process. IGF-1 LR3's extended half-life provides some carry-over effect, so a missed Monday injection still leaves residual plasma levels on Tuesday. Missing 3+ consecutive doses per week, however, drops plasma levels below the threshold needed for sustained satellite cell activation, which diminishes the protocol's effectiveness. Consistency across the 4–6 week cycle matters more than perfection on any single day.

Stack timing to avoid receptor competition. Ipamorelin pairs synergistically with CJC-1295 (a GHRH analog) because they act on different pituitary receptors, but should not be injected simultaneously with other ghrelin mimetics like GHRP-2. Research published in Peptides journal demonstrated that combining ipamorelin with CJC-1295 produced GH peaks 3.2× higher than ipamorelin alone, with sustained elevation lasting 4–6 hours versus 90 minutes for ipamorelin monotherapy. For combined protocols, consider CJC-1295/Ipamorelin blend formulations designed for receptor synergy.

Yes, and it's recommended. IGF-1 LR3's 20–30 hour half-life means plasma levels from a Monday injection remain elevated through Tuesday evening. Injecting on rest days maintains steady-state receptor saturation, which prevents the drop-off in satellite cell signaling that occurs when dosing only on training days. Research protocols that dose 5–6 days per week (including rest days) show superior cumulative hypertrophy compared to training-day-only protocols—the satellite cell proliferation window extends beyond the training stimulus itself.

IGF-1 LR3 stacks synergistically with peptides that target complementary pathways. BPC-157 enhances connective tissue repair and modulates inflammatory cytokines, addressing tendon and ligament recovery that IGF-1 LR3 doesn't directly target. Thymalin supports immune function and thymic peptide signaling, which can be suppressed during high-volume training blocks. Avoid combining IGF-1 LR3 with insulin or GH secretagogues without medical oversight—stacking compounds that all lower blood glucose or stimulate IGF-1 signaling creates hypoglycemia risk and receptor desensitisation.

Use a laminar flow hood or biosafety cabinet with active air filtration, which removes alcohol vapor in real time. If a fume hood isn't available, sterilize your workspace with 70% isopropyl alcohol, then introduce a cross-breeze using a small fan positioned 3–4 feet from the work surface. This accelerates vapor dispersion from 10 minutes to approximately 4 minutes. Alternatively, use hydrogen peroxide wipes instead of alcohol-based cleaners. 3% hydrogen peroxide provides equivalent antimicrobial action without leaving organic solvent residues that interact with peptide structures. Our facility protocols specify hydrogen peroxide for all peptide preparation areas specifically because it eliminates alcohol vapor risk entirely.

Bacteriostatic water should have no discernible odor beyond a faint medicinal smell from 0.9% benzyl alcohol. A strong alcohol smell suggests contamination with ethanol or isopropyl alcohol during manufacturing or storage. Potentially from shared production lines or improper sealing. Discard the vial and source a replacement from a verified supplier. Epithalon reconstituted in contaminated bacteriostatic water will show reduced binding affinity at pineal peptide receptors, rendering telomerase activation studies unreliable. At Real Peptides, we third-party test all diluents for solvent contamination before approving them for research use. A step that eliminates this exact failure mode.